Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice.

Although extensive evidence supports the role of β-amyloid (Aβ) in Alzheimer disease (AD), the neurotoxic mechanisms underlying AD pathogenesis are not understood. On the other hand, neuronal loss is the pathologic feature that best correlates with cognitive impairment. We hypothesized that cholinergic neurodegeneration may lead to Aβ deposition and tested this by inducing selective cholinergic lesions in APPswe/PS1dE9 mice with murine p75 saporin (mu p75-SAP). Intracerebroventricular lesions that removed approximately 50% of cholinergic innervation to the cortex and hippocampus were induced in animals with incipient (∼3 months) and marked (∼7 months of age) Aβ deposition. Cranial windows were implanted, and Aβ deposition was monitored in vivo using multiphoton microscopy. Deposition of Aβ was increased as soon as 7 days after the lesion, and this effect was maintained up to 3 months later. Postmortem studies using immunohistochemistry with an anti-Aβ antibody corroborated these findings in both cerebral cortex and hippocampus. Tau phosphorylation was also significantly increased after the lesions. Cholinergic denervation resulted in early memory impairment at 3 months of age that worsened with age (∼7 months); there was a synergistic effect between cholinergic denervation and the presence of APP/PS1 transgenes. Altogether, our data suggest that cholinergic denervation may trigger Aβ deposition and synergistically contribute to cognitive impairment in AD patients.

[1]  C. Ayata,et al.  Cerebrovascular lesions induce transient β-amyloid deposition. , 2011, Brain : a journal of neurology.

[2]  J. Wuu,et al.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. , 2011, The American journal of pathology.

[3]  M. Jucker,et al.  Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders , 2011, Annals of neurology.

[4]  S. DeKosky,et al.  Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease , 2011, Neurology.

[5]  Onofre Combarros,et al.  Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test , 2011, BMC neurology.

[6]  M. Sabbagh,et al.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease , 2011, Acta Neuropathologica.

[7]  Ying-Dong Zhang,et al.  Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains , 2011, Brain Research.

[8]  B. Hyman,et al.  Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice , 2010, Neurobiology of Aging.

[9]  Julie A. Harris,et al.  Transsynaptic Progression of Amyloid-β-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network , 2010, Neuron.

[10]  E. Capetillo-Zarate,et al.  Effects of Synaptic Modulation on β-Amyloid, Synaptophysin, and Memory Performance in Alzheimer's Disease Transgenic Mice , 2010, The Journal of Neuroscience.

[11]  R. Bernabeu,et al.  The p75 neurotrophin receptor is expressed by adult mouse dentate progenitor cells and regulates neuronal and non-neuronal cell genesis , 2010, BMC Neuroscience.

[12]  Qiao-Xin Li,et al.  Aβ1–42 stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor , 2009, Neurobiology of Aging.

[13]  A. Aguzzi,et al.  Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation , 2009, Proceedings of the National Academy of Sciences.

[14]  M. Baxter,et al.  Efficacy of a murine-p75-saporin immunotoxin for selective lesions of basal forebrain cholinergic neurons in mice , 2009, Neuroscience Letters.

[15]  B. Cosquer,et al.  Neuroanatomical and behavioral effects of a novel version of the cholinergic immunotoxin mu p75‐saporin in mice , 2008, Hippocampus.

[16]  Guojun Bu,et al.  Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.

[17]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[18]  S. DeKosky,et al.  Cholinergic forebrain degeneration in the APPswe/PS1ΔE9 transgenic mouse , 2007, Neurobiology of Disease.

[19]  B. Hyman,et al.  Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model , 2007, Journal of neurochemistry.

[20]  Brian J. Bacskai,et al.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease , 2006, Neurobiology of Disease.

[21]  M. Garcia-Alloza,et al.  Effect of Selective Cholinergic Denervation on the Serotonergic System: Implications for Learning and Memory , 2006, Journal of neuropathology and experimental neurology.

[22]  Joseph P. Huston,et al.  Integrated memory for objects, places, and temporal order: Evidence for episodic-like memory in mice , 2005, Neurobiology of Learning and Memory.

[23]  D. Borchelt,et al.  Environmental Enrichment Mitigates Cognitive Deficits in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[24]  D. Holtzman,et al.  Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. , 2005, The Journal of clinical investigation.

[25]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[26]  A. Granholm,et al.  Minocycline protects basal forebrain cholinergic neurons from mu p75‐saporin immunotoxic lesioning , 2004, The European journal of neuroscience.

[27]  A. Škoch,et al.  Classification of calf muscle MR images by texture analysis , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

[28]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[29]  D. German,et al.  Cholinergic neuropathology in a mouse model of Alzheimer's disease , 2003, The Journal of comparative neurology.

[30]  Bettina Schmitt,et al.  Selection of D‐Amino‐Acid Peptides That Bind to Alzheimer's Disease Amyloid Peptide Aβ1–42 by Mirror Image Phage Display , 2003, Chembiochem : a European journal of chemical biology.

[31]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[32]  D. Price,et al.  Disruption of Corticocortical Connections Ameliorates Amyloid Burden in Terminal Fields in a Transgenic Model of Aβ Amyloidosis , 2002, The Journal of Neuroscience.

[33]  D. Peterson,et al.  Evidence That Synaptically Released β-Amyloid Accumulates as Extracellular Deposits in the Hippocampus of Transgenic Mice , 2002, The Journal of Neuroscience.

[34]  H. Tanila,et al.  Fimbria–Fornix Lesion Does Not Affect APP Levels and Amyloid Deposition in the Hippocampus of APP+PS1 Double Transgenic Mice , 2002, Experimental Neurology.

[35]  B. Hyman,et al.  Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative , 2002, Journal of neuropathology and experimental neurology.

[36]  M. Baxter,et al.  Selective Immunolesions of Cholinergic Neurons in Mice: Effects on Neuroanatomy, Neurochemistry, and Behavior , 2001, The Journal of Neuroscience.

[37]  B T Hyman,et al.  Growth Arrest of Individual Senile Plaques in a Model of Alzheimer's Disease Observed by In Vivo Multiphoton Microscopy , 2001, The Journal of Neuroscience.

[38]  J. Growdon,et al.  The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease , 2000, Annals of neurology.

[39]  W. Honer,et al.  Cortical Cholinergic Denervation Elicits Vascular Aβ Deposition , 2000 .

[40]  G. Hu,et al.  Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex , 1999, Neuroscience Letters.

[41]  Steffen Roßner,et al.  The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling , 1998, Progress in Neurobiology.

[42]  G. Leanza.  Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions , 1998, Neuroscience Letters.

[43]  T. Deacon,et al.  Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system , 1998, Neuroreport.

[44]  L. Harrell,et al.  Cholinergic activity and amyloid precursor protein metabolism , 1997, Brain Research Reviews.

[45]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[46]  S. Heckers,et al.  Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  R. Wurtman.  Choline metabolism as a basis for the selective vulnerability of cholinergic neurons , 1992, Trends in Neurosciences.

[48]  B. Chozick.  The nucleus basalis of Meynert in neurological dementing disease: a review. , 1987, The International journal of neuroscience.

[49]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[50]  Peter Desain,et al.  Society for Neuroscience Meeting , 2010 .

[51]  S. DeKosky,et al.  Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. , 2007, Neurobiology of disease.

[52]  Mathias Hoehn,et al.  Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice , 2006, The Journal of Neuroscience.

[53]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.

[54]  K. Henke,et al.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.

[55]  W. Honer,et al.  Cortical cholinergic denervation elicits vascular A beta deposition. , 2000, Annals of the New York Academy of Sciences.